JP2008501712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501712A5 JP2008501712A5 JP2007515637A JP2007515637A JP2008501712A5 JP 2008501712 A5 JP2008501712 A5 JP 2008501712A5 JP 2007515637 A JP2007515637 A JP 2007515637A JP 2007515637 A JP2007515637 A JP 2007515637A JP 2008501712 A5 JP2008501712 A5 JP 2008501712A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- medicament
- exposure
- medicament according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 61
- 102000004965 antibodies Human genes 0.000 claims 61
- 239000003814 drug Substances 0.000 claims 46
- 102100000165 MS4A1 Human genes 0.000 claims 7
- 101710010909 MS4A1 Proteins 0.000 claims 7
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 4
- 108010036949 Cyclosporine Proteins 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 4
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 2
- 229960002170 Azathioprine Drugs 0.000 claims 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 2
- 229940112129 Campath Drugs 0.000 claims 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 Chlorambucil Drugs 0.000 claims 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims 2
- 229940119017 Cyclosporine Drugs 0.000 claims 2
- 229960005309 Estradiol Drugs 0.000 claims 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
- 229940088597 Hormone Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine zwitterion Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 229960001156 Mitoxantrone Drugs 0.000 claims 2
- 206010063401 Primary progressive multiple sclerosis Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 229960003604 Testosterone Drugs 0.000 claims 2
- 229940034208 Thyroxine Drugs 0.000 claims 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000002502 anti-myelin Effects 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 239000002458 cell surface marker Substances 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 108010074605 gamma-Globulins Proteins 0.000 claims 2
- 229960003776 glatiramer acetate Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000001861 immunosuppresant Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229950008325 levothyroxine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- 108010041012 Integrin alpha4 Proteins 0.000 claims 1
- 108010035649 Natalizumab Proteins 0.000 claims 1
- 210000004248 Oligodendroglia Anatomy 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 108010010371 efalizumab Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
Claims (38)
- 被験体における多発性硬化症を処置するための医薬であって、有効量のＣＤ２０抗体を被験体に投与して約０．５〜４グラムの最初の抗体暴露を与え、次いで約０．５〜４グラムの第２抗体暴露を与え、第２抗体暴露は最初の抗体暴露から約１６〜６０週まで与えられず、そして抗体暴露の各々は１または２用量の抗体として被験体に与えられることを特徴とする、医薬。
- 最初の抗体暴露から約２０〜３０週まで第二抗体暴露を与えない、請求項１に記載の医薬。
- 最初の抗体暴露および第二抗体暴露を、各々約１．５〜２．５グラムの量で与える、請求項１または２に記載の医薬。
- 医薬が、有効量のＣＤ２０抗体を被験体にさらに投与して約０．５〜４グラムの第３抗体暴露を与え、第３抗体暴露は最初の抗体暴露から約４０〜６０週まで行わないことを特徴とする、請求項２〜３のいずれか１つに記載の医薬。
- 第三抗体暴露を、約１．５〜２．５グラムの量で与える、請求項４に記載の医薬。
- 最初の抗体暴露から約４６〜５４週まで第三抗体暴露を与えない、請求項４または５に記載の医薬。
- さらなる抗体曝露を、最初の抗体暴露から少なくとも約７０〜７５週まで与えない、請求項４〜６のいずれか１つに記載の医薬。
- 最初の抗体暴露から約４６〜６０週まで第二抗体暴露を与えない、請求項１に記載の医薬。
- 抗体暴露の各々を１用量の抗体として被験体に与える、請求項１〜８のいずれか１つに記載の医薬。
- 抗体暴露の各々を２用量の抗体として被験体に与え、該２用量は第１用量と第２用量を構成する、請求項１〜８のいずれか１つに記載の医薬。
- 第１用量が投与された時から約３〜１７日に、第２用量を投与する、請求項１０に記載の医薬。
- 第１用量が投与された時から約６〜１６日に、第２用量を投与する、請求項１１に記載の医薬。
- 第１用量が投与された時から約１３〜１６日に、第２用量を投与する、請求項１２に記載の医薬。
- 第１用量の抗体および第２用量の抗体が各々約０．５〜１．５グラムである、請求項１０〜１３のいずれか１つに記載の医薬。
- 第１用量の抗体および第２用量の抗体が各々約０．７５〜１．３グラムである、請求項１０〜１４のいずれか１つに記載の医薬。
- ３回又は３回より多くの抗体暴露を被験体に対して行う、請求項１〜１５のいずれか１つに記載の医薬。
- ４回又は４回より多くの抗体暴露を被験体に対して行う、請求項１〜１６のいずれか１つに記載の医薬。
- 第２医薬を最初の抗体暴露又は後の抗体暴露と共に投与し、ＣＤ２０抗体が第１医薬である、請求項１〜１７のいずれか１つに記載の医薬。
- 第２医薬が、インターフェロン、酢酸グラチラマー、細胞毒性作用物質、化学療法剤、ミトキサントロン、メトトレキセート、シクロホスファミド、クロラムブシル、アザチオプリン、γグロブリン、カムパス（Campath）、抗ＣＤ４、クラドリビン、コルチコステロイド、ミコフェノレートモフェチル（ＭＭＦ）、シクロスポリン、スタチンクラスのコレステロール低下薬物、エストラジオール、テストステロン、ホルモン置換薬物、ＴＮＦ阻害剤、疾患改変抗リウマチ薬物（ＤＭＡＲＤ）、非ステロイド抗炎症性薬物（ＮＳＡＩＤ）、レボチロキシン、シクロスポリンＡ、ソマトスタチン（somatastatin）アナログ、サイトカインまたはサイトカイン受容体アンタゴニスト、代謝拮抗物質、免疫抑制剤、インテグリンアンタゴニストもしくは抗体、ＬＦＡ−１抗体、エファリズマブ、α４インテグリン抗体、ナタリズマブおよび他のＢ細胞表面マーカー抗体からなる群より選ばれる、請求項１８に記載の医薬。
- 多発性硬化症が再発−寛解多発性硬化症（ＲＲＭＳ）である、請求項１〜１９のいずれか１つに記載の医薬。
- 多発性硬化症が一次進行性多発性硬化症（ＰＰＭＳ）である、請求項１〜１９のいずれか１つに記載の医薬。
- 被験体はＣＤ２０抗体により決して前もって処置されていない、請求項１〜２１のいずれか１つに記載の医薬。
- 抗体が裸の抗体である、請求項１〜２２のいずれか１つに記載の医薬。
- 抗体が他の分子とコンジュゲートしている、請求項１〜２２のいずれか１つに記載の医薬。
- 他の分子が細胞毒性作用物質である、請求項２４に記載の医薬。
- 抗体を静脈内に投与する、請求項１〜２５のいずれか１つに記載の医薬。
- 抗体を、各抗体暴露のために静脈内に投与する、請求項２６に記載の医薬。
- 抗体を皮下に投与する、請求項１〜２５のいずれか１つに記載の医薬。
- 抗体を鞘内に投与する、請求項１〜２５のいずれか１つに記載の医薬。
- ＣＤ２０抗体が、多発性硬化症を処置するために被験体に投与される唯一の医薬である、請求項１〜２９のいずれか１つに記載の医薬。
- 抗体がリツキシマブである、請求項１〜３０のいずれか１つに記載の医薬。
- 抗体が、配列番号２および８における可変ドメイン配列を含むヒト化２Ｈ７である、請求項１〜３０のいずれか１つに記載の医薬。
- 抗体が、配列番号２３および２４における可変ドメイン配列を含むヒト化２Ｈ７である、請求項１〜３０のいずれか１つに記載の医薬。
- 被験体が、高められた抗ミエリン塩基性タンパク質（ＭＢＰ）、抗ミエリンオリゴデンドロサイト糖タンパク質（ＭＯＧ）、抗ガングリオシドおよび／または抗ニューロフィラメント抗体レベルを有する、請求項１〜３３のいずれか１つに記載の医薬。
- 高められたレベルのＢ細胞が、被験体の脳脊髄液（ＣＳＦ）、多発性硬化症病変または血清中に存在する、請求項１〜３４のいずれか１つに記載の医薬。
- （ａ）ＣＤ２０抗体を含む容器、および
（ｂ）被験体の多発性硬化症を処置するための指示を有するパッケージインサートであって、該指示は、約０．５〜４グラムの最初の抗体暴露を与え、次いで約０．５〜４グラムの第２抗体暴露を与えるのに有効な量の抗体を被験体に投与し、最初の抗体暴露から約１６〜６０週まで第２抗体暴露を行わず、そして抗体暴露の各々は１または２用量の抗体として被験体に与えられることを指示している、パッケージインサート、
を含む製造物。 - 第２医薬を含む容器をさらに含み、ＣＤ２０抗体が第１医薬であり、そして第２医薬により被験体を処置するためのパッケージインサートにおける指示をさらに含む、請求項３６に記載の製造物。
- 第２医薬が、インターフェロン、酢酸グラチラマー、細胞毒性作用物質、化学療法剤、ミトキサントロン、メトトレキセート、シクロホスファミド、クロラムブシル、アザチオプリン、γグロブリン、カムパス（Campath）、抗ＣＤ４、クラドリビン、コルチコステロイド、ミコフェノレートモフェチル（ＭＭＦ）、シクロスポリン、スタチンクラスのコレステロール低下薬物、エストラジオール、テストステロン、ホルモン置換薬物、ＴＮＦ阻害剤、疾患改変抗リウマチ薬物（ＤＭＡＲＤ）、非ステロイド抗炎症性薬物（ＮＳＡＩＤ）、レボチロキシン、シクロスポリンＡ、ソマトスタチン（somatastatin）アナログ、サイトカインまたはサイトカイン受容体アンタゴニスト、代謝拮抗物質、免疫抑制剤、および他のＢ細胞表面マーカー抗体からなる群より選ばれる、請求項３７に記載の製造物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57699304P | 2004-06-04 | 2004-06-04 | |
| PCT/US2005/019641 WO2005117978A2 (en) | 2004-06-04 | 2005-06-02 | Method for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501712A JP2008501712A (ja) | 2008-01-24 |
| JP2008501712A5 true JP2008501712A5 (ja) | 2008-07-17 |
Family
ID=35351693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515637A Pending JP2008501712A (ja) | 2004-06-04 | 2005-06-02 | 多発性硬化症を処置するための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20060051345A1 (ja) |
| EP (2) | EP1753455A2 (ja) |
| JP (1) | JP2008501712A (ja) |
| KR (3) | KR20150092374A (ja) |
| CN (3) | CN102512675A (ja) |
| AR (1) | AR049200A1 (ja) |
| AU (1) | AU2005249566B2 (ja) |
| BR (1) | BRPI0510915A (ja) |
| CA (1) | CA2566979A1 (ja) |
| IL (2) | IL179139A (ja) |
| MX (1) | MXPA06014069A (ja) |
| MY (1) | MY194883A (ja) |
| NO (1) | NO20070052L (ja) |
| NZ (1) | NZ604082A (ja) |
| RU (1) | RU2384345C2 (ja) |
| SG (1) | SG183012A1 (ja) |
| SV (1) | SV2006002132A (ja) |
| TW (2) | TWI433682B (ja) |
| WO (1) | WO2005117978A2 (ja) |
| ZA (1) | ZA200610158B (ja) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| PT1572744E (pt) * | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| SG10202008722QA (en) | 2003-11-05 | 2020-10-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
| US8398980B2 (en) | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
| AU2006204757A1 (en) * | 2005-01-13 | 2006-07-20 | Genentech, Inc. | Treatment method |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| PT1853250E (pt) | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| DK3279663T3 (da) | 2006-03-15 | 2021-10-18 | Brigham & Womens Hospital Inc | Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme |
| US8440622B2 (en) * | 2006-03-15 | 2013-05-14 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel) |
| EP2001510A4 (en) * | 2006-03-16 | 2010-06-09 | Genentech Inc | METHODS OF TREATING LUPUS USING CD4 ANTIBODIES |
| US20080279848A1 (en) * | 2006-03-16 | 2008-11-13 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
| ES2612383T3 (es) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1/IL-27 como una diana para respuestas antiinflamatorias |
| AU2007334360B2 (en) | 2006-12-14 | 2013-10-17 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
| US20090214561A1 (en) * | 2007-09-24 | 2009-08-27 | David Robert Close | Treatment method |
| WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| FI20075968A0 (fi) * | 2007-12-28 | 2007-12-28 | Licentia Oy | Menetelmä immunomodulaattorihoitojen tehokkuuden tarkkailemiseksi |
| US9575072B2 (en) | 2008-01-25 | 2017-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic and therapeutic uses of gelsolin in renal failure |
| WO2009102611A2 (en) * | 2008-02-15 | 2009-08-20 | Bayhill Therapeutics, Inc. | Methods of predicting responsiveness of ms patients to immune-based therapy |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| WO2010009129A2 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Methods of treating autoimmune diseases using cd4 antibodies |
| WO2010022398A1 (en) * | 2008-08-22 | 2010-02-25 | Isaac Melamed | Diagnosis and treatment of neuro-inflammatory disorders |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR20190130050A (ko) | 2010-06-04 | 2019-11-20 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| WO2012154215A1 (en) | 2011-05-04 | 2012-11-15 | Cellular Technology, Ltd. | Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis |
| EP2760478A1 (en) * | 2011-09-26 | 2014-08-06 | Universität Zürich Prorektorat MNW | Apc-mediated tolerance induction for therapy of multiple sclerosis |
| RU2014141056A (ru) * | 2012-03-12 | 2016-05-10 | МЕДИММЬЮН, ЭлЭлСи | Лечение рассеянного склероза при помощи антитела к cd19 |
| US20140271630A1 (en) * | 2013-03-12 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| MX2017013859A (es) * | 2015-04-29 | 2018-07-06 | 7 Hills Interests Llc | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
| RU2600160C1 (ru) * | 2015-08-07 | 2016-10-20 | Юрий Леонидович Шевченко | Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний |
| AU2016343633B2 (en) | 2015-10-30 | 2021-07-01 | Neurocrine Biosciences, Inc. | Valbenazine salts and polymorphs thereof |
| WO2017112857A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) |
| WO2018008017A1 (en) * | 2016-07-03 | 2018-01-11 | Hadasit Medical Research Services And Development Ltd. | Circulating micrornas as biomarkers for therapy in neuromyelitis optica (nmo) and multiple sclerosis (ms) |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| MX2020003462A (es) | 2017-01-27 | 2020-08-03 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS |
| MX2020002841A (es) | 2017-09-21 | 2020-07-22 | Neurocrine Biosciences Inc | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. |
| US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| KR20200066661A (ko) | 2017-10-10 | 2020-06-10 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| RU2721282C2 (ru) * | 2017-11-21 | 2020-05-18 | Илья Владимирович Духовлинов | Способ лечения рассеянного склероза (варианты) |
| WO2019133890A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Kansas | Nanoparticles including a glatiramoid useful in polynucleotide delivery |
| EP3836926A4 (en) * | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences, Inc. | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| KR20230048422A (ko) * | 2020-08-14 | 2023-04-11 | 에프. 호프만-라 로슈 아게 | 오크렐리주맙으로 다발성 경화증을 치료하는 방법 |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4690905A (en) * | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| ES2062519T5 (es) | 1989-03-21 | 2003-07-16 | Immune Response Corp Inc | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| AU652540B2 (en) | 1989-07-19 | 1994-09-01 | Xoma Corporation | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| JP3353209B2 (ja) | 1992-04-03 | 2002-12-03 | ジェネンテク，インコーポレイテッド | αｖβ３インテグリンに対する抗体 |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69329503T2 (de) * | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DE69534530T2 (de) * | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US20010056066A1 (en) | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
| AU5605398A (en) * | 1996-12-11 | 1998-07-03 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU757627B2 (en) | 1997-06-24 | 2003-02-27 | Genentech Inc. | Methods and compositions for galactosylated glycoproteins |
| WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE414536T1 (de) * | 1998-08-11 | 2008-12-15 | Biogen Idec Inc | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| JP2002529429A (ja) | 1998-11-09 | 2002-09-10 | アイデック・ファーマシューティカルズ・コーポレイション | Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。 |
| EP1949910A1 (en) | 1998-11-09 | 2008-07-30 | Biogen Idec, Inc. | Treatment of chronic lymphocytic leukemia (CLL) using chimeric anti-CD20 antibody. |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6383276B1 (en) | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| EP2275541B1 (en) * | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
| DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| CA2379274A1 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| JP2003513012A (ja) | 1999-08-11 | 2003-04-08 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
| US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
| AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| WO2001034194A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| DE60127656T2 (de) | 2000-02-25 | 2007-12-20 | Immunex Corp., Seattle | Integrin antagonisten |
| AU2001247737A1 (en) * | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
| US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| CN1981868A (zh) | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
| WO2001080884A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| EP2052742A1 (en) | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
| WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| JP2004502742A (ja) | 2000-07-12 | 2004-01-29 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願 |
| BRPI0113331B8 (pt) * | 2000-08-18 | 2021-05-25 | Ajinomoto Kk | derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica |
| US7332168B2 (en) * | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| AU2001290303A1 (en) | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| WO2002034790A1 (en) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
| KR100923514B1 (ko) | 2000-12-28 | 2009-10-27 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| NZ545176A (en) | 2001-01-29 | 2008-05-30 | Biogen Idec Inc | Modified antibodies reactive with CD20 and methods of use |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
| US20020197256A1 (en) | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
| WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
| JP2005515161A (ja) | 2001-06-14 | 2005-05-26 | インターミューン インコーポレイテッド | γ−インターフェロンおよびＢ細胞特異的抗体の併用療法 |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| WO2003010135A1 (fr) | 2001-07-26 | 2003-02-06 | Ajinomoto Co., Inc. | Nouveaux derives de l'acide phenylpropionique |
| NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| EP2131198B1 (en) * | 2001-09-20 | 2013-03-27 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| AU2002337935B2 (en) * | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| WO2003049694A2 (en) | 2001-12-07 | 2003-06-19 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| WO2003053926A1 (fr) * | 2001-12-13 | 2003-07-03 | Ajinomoto Co.,Inc. | Nouveau derive de phenylalanine |
| US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| JP4470219B2 (ja) | 2002-02-20 | 2010-06-02 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
| US20030180292A1 (en) | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| WO2003085107A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules à génome modifié |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| JPWO2003089410A1 (ja) | 2002-04-19 | 2005-08-25 | 協和醗酵工業株式会社 | フェニルアラニン誘導体 |
| US20030219818A1 (en) | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1558711A1 (en) * | 2002-10-08 | 2005-08-03 | ExxonMobil Research and Engineering Company | Heavy hydrocarbon composition with utility as a heavy lubricant base stock |
| MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| WO2004091657A2 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| AU2004252067B2 (en) | 2003-05-09 | 2012-04-12 | Duke University | CD20-specific antibodies and methods of employing same |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| ES2537738T3 (es) | 2003-06-05 | 2015-06-11 | Genentech, Inc. | Terapia de combinación para trastornos de células B |
| RU2370775C2 (ru) * | 2003-07-29 | 2009-10-20 | Дженентек, Инк. | Анализ нейтрализующих антител и его применение |
| CA2534898A1 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| AU2004270165A1 (en) | 2003-08-29 | 2005-03-17 | Genentech, Inc. | Anti-CD20 therapy of ocular disorders |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | HYBRID PROTEIN COMPOSITION |
| EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| EP1773393A2 (en) * | 2004-05-05 | 2007-04-18 | Genentech, Inc. | Preventing autoimmune disease by using an anti-cd20 antibody |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
-
2005
- 2005-06-02 KR KR1020157020875A patent/KR20150092374A/ko not_active Application Discontinuation
- 2005-06-02 US US11/143,386 patent/US20060051345A1/en not_active Abandoned
- 2005-06-02 CN CN2011104417566A patent/CN102512675A/zh active Pending
- 2005-06-02 RU RU2006147253/14A patent/RU2384345C2/ru active
- 2005-06-02 TW TW094118185A patent/TWI433682B/zh active
- 2005-06-02 KR KR1020137020073A patent/KR20130099228A/ko not_active Application Discontinuation
- 2005-06-02 AR ARP050102270A patent/AR049200A1/es unknown
- 2005-06-02 SG SG2012050688A patent/SG183012A1/en unknown
- 2005-06-02 CA CA002566979A patent/CA2566979A1/en not_active Abandoned
- 2005-06-02 NZ NZ604082A patent/NZ604082A/en unknown
- 2005-06-02 ZA ZA200610158A patent/ZA200610158B/en unknown
- 2005-06-02 SV SV2005002132A patent/SV2006002132A/es unknown
- 2005-06-02 KR KR1020067025348A patent/KR20070029733A/ko not_active Application Discontinuation
- 2005-06-02 EP EP05756597A patent/EP1753455A2/en not_active Ceased
- 2005-06-02 JP JP2007515637A patent/JP2008501712A/ja active Pending
- 2005-06-02 CN CNA2005800266023A patent/CN1993143A/zh active Pending
- 2005-06-02 AU AU2005249566A patent/AU2005249566B2/en active Active
- 2005-06-02 CN CN201610550354.2A patent/CN106075435A/zh active Pending
- 2005-06-02 MY MYPI20052531A patent/MY194883A/en unknown
- 2005-06-02 TW TW102143567A patent/TW201422238A/zh unknown
- 2005-06-02 EP EP16179276.7A patent/EP3130349A1/en not_active Withdrawn
- 2005-06-02 WO PCT/US2005/019641 patent/WO2005117978A2/en active Application Filing
- 2005-06-02 BR BRPI0510915-9A patent/BRPI0510915A/pt not_active Application Discontinuation
- 2005-06-02 MX MXPA06014069A patent/MXPA06014069A/es active IP Right Grant
-
2006
- 2006-11-09 IL IL179139A patent/IL179139A/en active IP Right Grant
-
2007
- 2007-01-03 NO NO20070052A patent/NO20070052L/no not_active Application Discontinuation
-
2010
- 2010-02-26 US US12/713,366 patent/US20100233121A1/en not_active Abandoned
-
2012
- 2012-04-05 US US13/440,916 patent/US20120199516A1/en not_active Abandoned
- 2012-04-19 IL IL219285A patent/IL219285A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501712A5 (ja) | ||
| JP2016147856A5 (ja) | ||
| RU2006147253A (ru) | Способ лечения рассеянного склероза | |
| Minagar | Current and future therapies for multiple sclerosis | |
| Piehl | A changing treatment landscape for multiple sclerosis: challenges and opportunities | |
| KR102276161B1 (ko) | 항체 제형 및 방법 | |
| Jones et al. | New treatment strategies in multiple sclerosis | |
| JP2008515890A5 (ja) | ||
| Gensicke et al. | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis | |
| JP2007512243A5 (ja) | ||
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| US6548527B2 (en) | Treatments for immune-mediated ear disorders | |
| CN109963577B (zh) | 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法 | |
| JP2015172060A5 (ja) | ||
| JP2019167385A (ja) | カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療 | |
| EP3868403A1 (en) | Taci-fc fusion protein and use thereof | |
| WO1995009652A1 (en) | Treatment of autoimmune and inflammatory disorders | |
| AU2020323596A1 (en) | Methods and compositions for reducing immunogenicity by non-depletional B cell inhibitors | |
| US20080286281A1 (en) | Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation | |
| Findling et al. | Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? | |
| Sans-Pola et al. | Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review | |
| Gonsette | Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis | |
| Graves et al. | Immunotherapies in neurologic disorders | |
| Moser | Options for induction immunosuppression in liver transplant recipients | |
| Stuart | Combination therapy for the treatment of multiple sclerosis: challenges and opportunities |